BOTHELL, WA--(Marketwire - November 24, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will present at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will participate in a “fireside” chat with Ted Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray.
A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company’s website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one and a half hours after the live presentation and will be archived for three months.
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech’s goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Contact:
Marina Biotech, Inc.:
Pete Garcia
Chief Financial Officer
(425) 908-3603
